74 articles - From Friday Aug 25 2023 to Friday Sep 01 2023
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Gastrointest Endosc |
|---|
meta-analyses and systematic reviews
| Hepatology |
|---|
Medications for alcohol use disorder promote abstinence in alcohol-related cirrhosis: results from a systematic review and meta-analysis. MAUD in patients with cirrhosis are effective in promoting AA and have a good safety profile. Larger studies on the effects of MAUD are needed, especially in patients with advanced liver disease. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy. Integrated HBV DNA and cccDNA maintain transcriptional activity and maybe involved in HBsAg seroreversion in intrahepatic HBsAg-positive patients with functional cure and linked to virological relapse. |
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. In intention-to-diagnose analysis, FibroTest-T2D, TD-SWE and VCTE performed similarly for staging fibrosis, and out-performed Fibrosis-4 in outpatients with type 2 diabetes. The standard analysis over-estimated VCTE performance. Clinicaltrial gov NCT03634098. |
Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis. Patients in grey zone of Baveno VII criteria remain at high risk of hepatic decompensation. Clinical risk factors and spleen stiffness can further stratify the risk in such patients. |
| Am J Gastroenterol |
A Review of Available Medical Therapies to Treat Moderate to Severe Inflammatory Bowel Disease in 2023. Additionally, safety considerations and use in special populations is summarized with proposed algorithms for positioning therapies. The aim is to provide a synopsis of high impact data and aid in outpatient treatment decision making for IBD patients. |
Endoscopist and procedure-level factors associated with increased adenoma detection with the use of a computer-aided detection (CADe) device. The application of CADe devices in clinical practice should be carefully evaluated. Larger studies should explore differences in endoscopist-related factors for CADe. |
Interventional Endoscopic Ultrasound: Current Status and Future Frontiers. Interventional Endoscopic Ultrasound (EUS) has fueled remarkable advancements in the field of therapeutic procedures, revolutionizing minimally invasive interventions for a diverse range of conditions. This review highlights the latest breakthroughs and advancements in therapeutic EUS, showcasing its potential to transform patient care. |
| Clin Gastroenterol Hepatol |
COLORECTAL CANCER STAGE-DISTRIBUTION AT FIRST AND REPEAT FECAL IMMUNOCHEMICAL TEST SCREENING. FIT-based screening is effective in downstaging CRC, also at repeat screening. Increasing the FIT cut-off level has limited impact on the stage-distribution of detected CRCs, though greatly affects CRC detection and thus is important to keep low. |
| Gastroenterology |
Development and validation of a post-radiotherapy prediction model for bowel dysfunction after rectal cancer resection. PORTLARS could predict major bowel dysfunction after rectal cancer resection following radiotherapy with high accuracy and robustness. It may serve as a useful tool to highlight patients who need additional support for long-term dysfunction in the early stage. |
Pancreatic acinar cells-derived sphingosine-1-phosphate contributes to fibrosis of chronic pancreatitis via inducing autophagy and activation of pancreatic stellate cells. Activated SPHK1/S1P pathway in iPACs induces autophagy and activation of PSCs by regulating S1PR2/AMPK/mTOR pathway, which promoting fibrogenesis of CP. The hypoxia microenvironment might contribute to the crosstalk between PACs and PSCs in pathogenesis of CP. |
The natural disease course of pancreatic cyst associated neoplasia, dysplasia, and ductal adenocarcinoma; results of a microsimulation model. The mean duration of HGD lesions prior to development of PC was estimated to be 4.0 years. This implies a window of opportunity for screening, presuming the availability of a reliable diagnostic test. The probability that LGD cyst will progress to cancer was predicted to be low. |
| Gut |
Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial. A combination of endoluminal RFA and stenting was not superior to stenting alone in prolonging survival or improving stent patency in patients with malignant biliary obstruction. |
Gastrointestinal syndromes preceding a diagnosis of Parkinson's disease: testing Braak's hypothesis using a nationwide database for comparison with Alzheimer's disease and cerebrovascular diseases. Dysphagia, gastroparesis, IBS without diarrhoea and constipation might specifically predict Parkinson's disease. |
| Hepatology |
HDV RNA Assays: Performance characteristics, clinical utility and challenges. We summarize distinct technical features and performance characteristics of available HDV RNA assays. Finally, we provide considerations for the use of HDV RNA assays in the context of drug development and patient monitoring. |
Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis. Finite Nuc therapy in HBeAg-negative HBV-LC may reduce HCC incidence, increase HBsAg loss and improve survival. Greater HBsAg decline/loss may reflect enhanced immunity and contribute to the reduction of hepatic carcinogenesis. |
Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression. Our results demonstrate that the PNPLA3 polymorphism in the absence of additional metabolic risk factors is insufficient to drive the development of advanced liver disease in severe alpha1-antitrypsin deficiency. |
Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites. RH was associated with higher risk of LRD than RA at equivalent MELD-Na. By contrast, MELD 3.0 may better predict risk of LRD in RH. |
| J Hepatol |
Familial Coaggregation of MASLD with Hepatocellular Carcinoma and Adverse Liver Outcomes: Nationwide Multigeneration Cohort Study. There is distinct familial clustering of adverse liver-related outcomes in families of individuals with biopsy-proven MASLD with higher relative risks of HCC, progressive liver disease, and liver-related mortality, but absolute risks are low. Impact and implications Metabolic dysfunction-associated steatotic liver disease (MASLD; formerly termed Nonalcoholic fatty liver disease; NAFLD) clusters in families with high genetic susceptibility and shared environmental risk factors, but the risks of developing hepatocellular carcinoma (HCC) and other major liver-related outcomes in family members of individuals with MASLD are largely unknown. This large nationwide multigeneration cohort study involving family members (first-degree relatives and spouses) of individuals with biopsy-proven MASLD and of matched general population comparators found slightly increased risks of HCC in first-degree relatives, and of developing cirrhosis and liver-related mortality in al family members of individuals with biopsy-proven MASLD. The findings of this study provide large-scale evidence to inform clinical practice guidelines for recommendations on the early identification of individuals at higher risk of liver-related morbidity and mortality. |
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab. Molecular-based guided therapy is feasible in patients with HCC/H-CCK progressing under atezolizumab/bevacizumab and may be useful in a small subset of patients. Impact and implications Whole genome/exome and RNA sequencing in clinical practice have never been previously reported in patients with HCC and H-CCK. Herein, we provided a pilot study suggesting that Whole genome/exome RNA sequencing is feasible on tumor biopsy in patients refractory to atezolizumab/bevacizumab with a small subset of the patients with at least one actionable genomic alteration and who received an adapted targeted therapy. This is a proof-of-concept study suggesting that a small subset of patients have a clinical benefit from this strategy. Finally, validation of this approach will be required in a larger cohort of patients. |
| J Neurogastroenterol Motil |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury. Our current understanding of HRS treatment is improved by recent randomized clinical trials. Previous studies using varying medication doses along with the "old" definition of hepatorenal syndrome (HRS type 1) rather than HRS-AKI means that there is still a need for future multicenter prospective studies further refining the risk-benefit ratio of vasoconstrictors for HRS-AKI patients. The Food and Drug Administration has approved terlipressin for use in September 2022. Because it will take time to adapt into clinical practice, less cost-prohibitive vasoconstrictors should still be considered. Opportunities also exist to clarify the safety, timing of initiation, as well as possible discontinuation of terlipressin. |
Hepatorenal Syndrome-Acute Kidney Injury in Liver Transplantation. Terlipressin has been shown to reverse HRS-AKI in a significant proportion of those treated and consequently can lead to increased LT patient survival and freedom from renal replacement therapy. We will review the impact of HRS on the management of patients awaiting LT, present strategies to prevent this significant complication, and discuss major implications of recent therapeutic advances in the setting of LT. |
Pathophysiology of Hepatorenal Syndrome - Acute Kidney Injury. Other contributing factors to renal dysfunction include the tubular damaging effects of cholestasis and adrenal dysfunction. Future developments include the use of metabolomics to identify metabolic pathways that can lead to the development of renal dysfunction, with the potential of identifying biomarkers for early diagnosis of renal dysfunction and the development of treatment strategies. |
The Diagnosis and Non-pharmacological Management of Acute Kidney Injury in Patients with Cirrhosis. The diagnosis and early institution of nonpharmacologic and pharmacologic management are key to the recovery of renal function. The objective of this review is to provide a practical approach to the use of diagnostic biomarkers and highlight the nonpharmacologic management and prevention of acute kidney injury. |
| Gastroenterology |
Gastric Intestinal Metaplasia: Real Culprit or Innocent Bystander as a Precancerous Condition for Gastric Cancer? Endoscopic surveillance for GIM may therefore be necessary, especially when there is extensive corpus GIM. Recent advances in image-enhanced endoscopy with integrated artificial intelligence have facilitated the identification of GIM and neoplastic lesions, which will impact preventive strategies in the near future. |
| Gut |
Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing. Although none of these new levels of healing indicate a definitive cure of the diseases, they make an important contribution to the assessment of patients' prognosis. The ultimate level of healing in IBD would be a resolution of al aspects of intestinal and extraintestinal inflammation (complete healing). |
| J Hepatol |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endoscopy |
| Gastroenterology |
| Gut |
| Hepatology |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Gastroenterology |
| Gut |
| J Hepatol |